Stritzke Amelie, Mohammad Khorshid, Shah Prakesh S, Ye Xiang Y, Bhandari Vineet, Akierman Albert, Harrison Adele, Bertelle Valerie, Lodha Abhay
a Department of Pediatrics, Section of Neonatology, Foothills Medical Centre , Cumming School of Medicine, University of Calgary , Calgary , Canada.
b Department of Paediatrics , Institute of HPME, University of Toronto, Mount Sinai Hospital , Toronto , Canada.
J Matern Fetal Neonatal Med. 2018 Nov;31(21):2862-2869. doi: 10.1080/14767058.2017.1358266. Epub 2017 Jul 31.
Use, timing and doses of surfactant in preterm infants are variable in practice in modern NICUs.
The objective of this study is to explore the association between use and timing of surfactant administration and common neonatal adverse outcomes in preterm infants with gestational age (GA) < 28 weeks.
Neonates admitted to a participating Canadian Neonatal Network NICU between 2013 and 2015 were studied. Infants were divided into three groups based on surfactant administration: none, early (within 30 min of life), and late surfactant (>30 min). The primary outcome was a composite of ≥2 predefined outcomes: bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) and severe neurological injury (intraventricular hemorrhage or intraventricular hemorrhage (IVH) grade III/IV ± periventricular leukomalacia).
Of 2512 eligible neonates, 430 were in the early, and 1228 were in the late surfactant group. There was no difference in the primary outcome (p = .88). There was a slightly lower risk of late onset sepsis [25% versus 29%, adjusted odds ratio (aOR): 0.8; 95% CI: 0.6-0.9] and ROP (12.4 versus 15%, aOR: 0.7; 95% CI: 0.5-0.9) in the early surfactant group.
In preterm neonates, early administration of surfactant within 30 min of life was not associated with an increased risk of the primary composite outcome, but did have decreased rates of late onset sepsis and ROP.
在现代新生儿重症监护病房(NICU)的实际操作中,早产儿使用表面活性剂的情况、时机和剂量各不相同。
本研究的目的是探讨胎龄(GA)<28周的早产儿使用表面活性剂的情况和给药时机与常见新生儿不良结局之间的关联。
对2013年至2015年期间入住参与加拿大新生儿网络NICU的新生儿进行研究。根据表面活性剂给药情况将婴儿分为三组:未使用、早期(出生后30分钟内)和晚期表面活性剂(>30分钟)。主要结局是≥2个预定义结局的综合:支气管肺发育不良(BPD)、早产儿视网膜病变(ROP)和严重神经损伤(脑室内出血或脑室内出血(IVH)III/IV级±脑室周围白质软化)。
在2512名符合条件的新生儿中,430名属于早期,1228名属于晚期表面活性剂组。主要结局无差异(p = 0.88)。早期表面活性剂组晚期败血症[25%对29%,调整优势比(aOR):0.8;95%置信区间(CI):0.6 - 0.9]和ROP(12.4%对15%,aOR:0.7;95%CI:0.5 - 0.9)的风险略低。
在早产儿中,出生后30分钟内早期给予表面活性剂与主要综合结局风险增加无关,但晚期败血症和ROP的发生率确实降低。